Dividends & Buybacks ·
Sangrix Inc. proposes 10-for-1 reverse share split effective November 13, 2026 to maintain Nasdaq listing
BTOGSangrix Inc.
Sangrix Inc. is soliciting shareholder approval for a proposed 10-for-1 reverse share consolidation of its Class A and Class B ordinary shares at an extraordinary general meeting on November 3, 2026. The transaction aims to increase the market price per share to satisfy Nasdaq’s $1.00 minimum bid price requirement and avoid immediate delisting. If approved, the consolidation will take effect on November 13, 2026, reducing authorized shares from 200 billion to 20 billion while maintaining the US$60 million total par value. The company also seeks approval to amend its memorandum and articles of association to reflect these changes. Sangrix Inc. operates in the artificial intelligence sector.